Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Jesus C. Fabregas"'
Autor:
Ellery Altshuler, Andrea N. Riner, Kelly M. Herremans, Thomas J. George, Sherise C. Rogers, Alessandro Paniccia, Steven J. Hughes, Jesus C. Fabregas, Ibrahim Nassour
Publikováno v:
Journal of Gastrointestinal Oncology. 13:3207-3215
Autor:
Brian H Ramnaraign, Ji-Hyun Lee, Azka Ali, Sherise C Rogers, Jesus C Fabregas, Ryan M Thomas, Carmen J Allegra, Ilyas Sahin, David L DeRemer, Thomas J George, Jonathan A Chatzkel
Publikováno v:
Future Oncology. 18:3815-3822
Immune checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance and the inhibition of this interaction is an effective treatment strategy for numerous malignancies.
Autor:
Livingstone Aduse-Poku, Shama D. Karanth, Meghann Wheeler, Danting Yang, Caretia Washington, Young-Rock Hong, Todd M. Manini, Jesus C. Fabregas, Ting-Yuan David Cheng, Dejana Braithwaite
Publikováno v:
Cancers
Volume 15
Issue 4
Pages: 1081
Volume 15
Issue 4
Pages: 1081
Purpose: The importance of body composition on cancer outcomes is of great clinical interest. Measures of body composition that differentiate fat mass from skeletal muscle mass can help redefine our understanding of body composition for cancer surviv
Publikováno v:
Journal of Racial and Ethnic Health Disparities. 9:2291-2299
Background Black patients are diagnosed with melanoma at a later stage, as compared with their white counterparts. It is unknown if Medicaid expansion might ameliorate this disparity. Methods Using data from the 2016 National Cancer Database, we cond
Autor:
Michael Jonathan Kucharczyk, Andrew Bang, Michael C. Tjong, Stefania Papatheodoru, Jesus C. Fabregas
Publikováno v:
Oncotarget. 13
The total mesorectal excision (TME) significantly improved rectal cancer outcomes. Radiotherapy's benefit in T3N0 rectal cancer patients managed with TME has not been clearly demonstrated. A systematic review and meta-analysis were undertaken to dete
Autor:
Ellery Altshuler, Raymond Richhart, Mahmoud Aryan, William King, Kelsey Pan, Akash Mathavan, Akshay Mathavan, Diana Rodriguez, Bishal Paudel, Nathan Northern, Brian Ramnaraign, Ilyas Sahin, Jesus C Fabregas
Publikováno v:
Journal of hepatocellular carcinoma. 9
Ellery Altshuler,1 Raymond Richhart,1 Mahmoud Aryan,2 William King,1 Kelsey Pan,1 Akash Mathavan,1 Akshay Mathavan,1 Diana Rodriguez,1 Bishal Paudel,1 Nathan Northern,1 Brian Ramnaraign,3 Ilyas Sahin,3 Jesus C Fabregas3 1Department of Internal Medici
Autor:
Girijesh Kumar Patel, Leander Grimm, Omar Alkharabsheh, Pranitha Prodduturvar, Wadad Mneimneh, Shalla Akbar, Paul Rider, Moh’d M. Khushman, Jesus C. Fabregas, Valeria Dal Zotto, Ajay P. Singh, John Hunter
Publikováno v:
Oncotarget
Introduction: Exosomes have pivotal roles in cancer development. The impact of neoadjuvant concurrent chemoradiation (NCCR) on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma are yet
Autor:
Sherise C. Rogers, Shu Wang, Ryan Michael Thomas, Brian Hemendra Ramnaraign, Jesus C. Fabregas, Ilyas Sahin, Stephen Staal, Martina Cathryn Murphy, Anna Melissa Singson Murillo, Merry Jennifer Markham, Frederic J. Kaye, Coy D. Heldermon, Dennie V. Jones, Julia Lee Close, Carmen Joseph Allegra, Thomas J. George
Publikováno v:
Journal of Clinical Oncology. 41:TPS280-TPS280
TPS280 Background: Patients with advanced colorectal cancer after progressing through first line therapy, have several FDA-approved systemic therapies that are associated with clinical benefit for a substantive minority of patients. Current clinical
Autor:
Muhammet Ozer, Suleyman Yasin Goksu, Jesus C. Fabregas, Brian Hemendra Ramnaraign, Sherise C. Rogers, Thomas J. George, Ilyas Sahin
Publikováno v:
Journal of Clinical Oncology. 41:525-525
525 Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the incidence of liver cancer is rapidly rising in the United States. Advanced HCC generally has a dismal prognosis with an expected survival of less
Autor:
Brian Hemendra Ramnaraign, Ji-Hyun Lee, Azka Ali, Sherise C. Rogers, Jesus C. Fabregas, Ryan M. Thomas, Carmen Joseph Allegra, David L. DeRemer, Thomas J. George, Jonathan Alexander Chatzkel
Publikováno v:
Journal of Clinical Oncology. 41:TPS625-TPS625
TPS625 Background: Immune checkpoint inhibitor (ICI) therapy represents a significant advance in cancer care however it is not an effective intervention in the treatment of several immunologically cold tumors including pancreatic, gallbladder, and bi